Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $613.96M.
ENTERPRISE VALUE (EV)
$613.96M
ArriVent BioPharma, Inc.
Market Cap
$659.50M
Enterprise Value (EV)
$613.96M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $659.50M | $613.96M |
| Starling Oncology, Inc. (STLN)vs › | $655.05M | $718.43M |
| MiMedx Group, Inc. (MDXG)vs › | $664.48M | $530.14M |
| Annexon, Inc. (ANNX)vs › | $667.25M | $492.63M |
| Helus Pharma Inc. (HELP)vs › | $668.81M | $502.64M |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $668.99M | $637.84M |
| OmniAb, Inc. (OABI)vs › | $641.50M | $636.08M |
| Aura Biosciences, Inc. (AURA)vs › | $636.65M | $585.41M |
| Solid Biosciences Inc. (SLDB)vs › | $683.73M | $544.49M |
| Prime Medicine, Inc. (PRME)vs › | $635.18M | $700.20M |
Market Cap
$659.50M
Total Debt
$0.00
Cash
$45.54M
Enterprise Value
$613.96M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
